In the Spotlight
- Mayes College Goes International with Global Program to China
- BioAdvance Names Dr. Philip Gerbino Chair
- Expert Commentary: Assessing the Effects of the Stimulus on Healthcare
- Dr. Shannon Márquez Named Associate Dean for Academic Affairs of Mayes College
- Travel Grant Helps Grad Student Carrie Waterman to ASP Meeting in Athens
- Pharmaceutics Graduate Student Preeti Desai presented at the NJPhAST meeting in May
- Spotlight on Graduate Student Shilpa Viswanathan and her UN Internship Experience
- Vijaya Swaminathan Successfully Defends her Thesis and Earns her PhD in Pharmaceutics
- Two USP graduate students in the Chemistry programs win awards
- Pharmaceutical Business Online MBA Spring 2008
- Studying Health Care In Japan
- Healthcare Regulation in America
BioAdvance Names Dr. Philip Gerbino Chair
BioAdvance, the Biotechnology Greenhouse Corporation of Southeastern Pennsylvania, announced on April 16, 2009, that Philip P. Gerbino, PharmD., has been elected as Chair of the organization’s Board of Directors effective April 2009. BioAdvance also announced that John M. Daly, M.D., has joined the organization’s Board of Directors.
“We are honored to have Dr. Gerbino serve as Chair of the Board of Directors as he is nationally recognized for his professional accomplishments, and he is a tremendous advocate for the Greater Philadelphia region’s scientific strengths. He will be a strong voice for BioAdvance’s activities and a driving force for our organization’s future goals,” said Barbara S. Schilberg, managing director and CEO of BioAdvance.
As President of University of the Sciences in Philadelphia for the past 14 years, Dr. Gerbino has helped guide the growth of the 188-year-old institution from its roots as Philadelphia College of Pharmacy and Science (PCPS) into the five colleges that now comprise the University. Dr. Gerbino is a Fellow of the College of Physicians of Philadelphia, the American Pharmacists Association (APhA), Academy of Pharmacy Practice and Management, and the American Society of Consultant Pharmacists (ASCP). He was the 2006 recipient of the Phi Lambda Sigma-Procter & Gamble National Leadership Award.
“I look forward to the opportunities ahead as BioAdvance expands on its successes of investing in and growing our region’s next-generation of leading biosciences companies, as well as in advancing the region’s prominence as a hub for life science discovery and entrepreneurship,” said Dr. Gerbino, who has served on BioAdvance’s Board of Director’s for the past six years. “BioAdvance has successfully helped its portfolio companies attract nearly $1 billion in additional capital to the region, built bridges between academic institutions and businesses through initiatives such as the Greater Philadelphia Bioinformatics Alliance and the Greater Philadelphia Life Sciences Guide, and led two Milken Institute studies on the impact of biosciences on our region. This dedication and leadership fulfills our covenant which fosters commercialization and regional economic development.”
Dr. Gerbino continues to serve on editorial and advisory boards of pharmacy, medical, and healthcare publications, and is a consultant on strategic planning, marketing, and new business development to the pharmaceutical and healthcare industries. He has or continues to serve on boards of private and public healthcare companies, and regional professional and civic organizations, including the University City Science Center, the University City Keystone Innovation Zone, Quaker BioVentures, and Pennsylvania Bio.
An accomplished professional chairman and facilitator, Dr. Gerbino has published and lectured extensively. He served as President of APhA in 1990, and as a civilian pharmacy consultant to the Air Force Surgeon General. Prior to being named President at University of the Sciences, he served as Dean of the School of Pharmacy and Vice President of Academic Affairs. He also retains the title of “Linwood F. Tice Professor” at the Philadelphia College of Pharmacy. Dr. Gerbino earned his B.S. in Pharmacy and his PharmD. from PCPS where he has worked for more than 30 years as an educator and administrator.
John M. Daly, MD, FACS, FRCPS (Hon. Glasg.), has also joined BioAdvance as a board member. “Dr. Daly is a terrific addition to the BioAdvance Board of Directors,” said Ms. Schilberg. “Since he joined Temple University School of Medicine as Dean in 2002, the institution has increased its funding from NIH and has expanded its research focus in important disease areas such as obesity, virology and oncology, as well as clinical translational research. We look forward to increased opportunities to work with Temple in advancing innovative new biomedical products.”
About BioAdvance
Since its first investments in 2003, BioAdvance has committed $15.5 million to 25 life sciences companies and 15 pre-seed projects. BioAdvance investments have enabled its portfolio companies to leverage almost $1 billion in subsequent capital into the region from private equity, grants, collaborations and M&A activity. Six companies have been acquired, including Acuity Pharmaceuticals, Alteris Therapeutics, and Protez Pharmaceuticals. BioAdvance portfolio companies are working to develop products to treat health problems including Alzheimer’s disease, cancer, diabetes, head trauma and infectious diseases. For more information visit www.bioadvance.com.
Written By: Ellen Semple
Contact: Bill Berry
Contact Phone: 212-253-8881
Mayes College Goes International with Global Program to China
Did you know...
You can earn two credit hours and have the opportunity to critically observe the Chinese healthcare system through participation in scheduled trips and one-on-one interaction with representatives from hospitals, the Ministry of Health, the local pharmaceutical business industry, western pharmaceutical companies, Shanghai University of Traditional Medicine, and Beijing University through participation in the upcoming Mayes Global Program to China?
Chinese Healthcare: A Study Tour to Shanghai & Beijing People's Republic of China June 26 -July 5, 2009
BRIEF PROGRAM DESCRIPTION
This two-credit summer study tour will provide an opportunity to study various aspects of the Chinese healthcare system - including the contrast of eastern and western medicine practices in Chinese healthcare, an overview of the pharmaceutical industry, health policy, health governance and reform, the healthcare and life insurance system, as well as cross-cultural training, customs, and etiquette. Students will have the opportunity to critically observe the Chinese healthcare system through participation in scheduled trips and one-on-one interaction with representatives from hospitals, the Ministry of Health, the local pharmaceutical business industry, western pharmaceutical companies, Shanghai University of Traditional Medicine, and Beijing University. Cultural excursions include lectures on etiquette, business customs, and Chinese progress and challenges, and visits to Yu Yuan Gardens, Tiananmen Square, Forbidden City, and the Great Wall.
LEARNING OBJECTIVES
- Compare and analyze the use of eastern and western medicine in the Chinese healthcare system.
- Describe the regulation and re-shaping of Chinese healthcare and the pharmaceutical industry.
- Discuss the impact of socio-cultural factors related to healthcare, business, and policy in China.
- Examine the similarities and differences between Chinese and US healthcare finance and reform.
ELIGIBILITY & PROGRAM REQUIREMENTS
To be eligible, applicants must:
- Be enrolled as a matriculated student (in good standing, and not on academic and/or disciplinary probation or warning) at a US college/university that is accredited by a regional accrediting organization recognized by the US Department of Education.
- Plan to attend the full program of study while abroad and be registered for academic credit. Undergraduate, graduate, and first professional degree students will be required to register for two (2) credit hours, although the course requirements and deliverables for graduate students may be higher than for undergraduate and first professional degree students, based on how the credits will be used in partial fulfillment of specific degree requirements. Students should discuss with their academic advisor/program director how this two-credit study tour will be applied towards their degree requirements. Students should register for this two-credit study tour only after they have received approval from their academic program director.
- Meet all additional, program/course requirements, including attending all pre-departure and in-country orientation activities, specific program deadlines, and complying with insurance requirements, etc.
Applications are currently being accepted. For application materials and information, please contact Prof. Bruce Rosenthal at b.rosent@usp.edu or Cassandra Henderson at c.hender@usp.edu.
Contact: Bruce Rosenthal
Contact Email: b.rosent@usp.edu
Expert Commentary: Assessing the Effects of the Stimulus on Healthcare
Written By: Dr. Robert Field
According to Dr. Robert Field of the Mayes College of Healthcare Business and Policy at University of the Sciences, the $787 billion stimulus package that President Barack Obama signed on Feb. 17 included both short and long-term healthcare provisions.
On the short-term implications:
“The short-term provisions assist people who will have trouble accessing healthcare because of the economic downturn. This includes subsidies for people who are laid off and use COBRA to extend coverage. COBRA premiums can be very expensive. It also includes assistance for states in covering Medicaid costs. Medicaid rolls will likely expand as more laid off workers are thrown into poverty. It also includes funding for care for underserved populations, including the elderly and those living in underserved regions.”
On what it means for the future:
“The long-term provisions are of more strategic importance. They have profound implications for the future of the American healthcare system. One major set of provisions encourages the broader adoption of health information technology. It provides large incentive for physicians and hospitals to computerize their medical records. It also implements penalties in a few years for those who do not. These are in the form of lower Medicare reimbursement. Observers have been complaining for many years that healthcare is much slower than many other industries in adopting IT. For about 20 years, customers have been able to access basic information about their bank accounts through ATMs. For about 10 years, they have been able to access complete information about their investment accounts with financial institutions. Of course, we would hardly want to use banking as the model of an industry to emulate right now. However, it seems odd that most patients cannot access their health information electronically or even schedule appointments online, when they can book airline tickets or hotel rooms this way with ease.”
On the result of changes to information technology:
“Increased use of IT has the potential to substantially improve healthcare quality. Many of the thousand of errors that are made each year result from poor communication among providers and poor coordination of care. IT will greatly help with this. On the other hand, IT will probably not reduce costs. Over the next few years, it will likely cost more to implement than it saves. This is not to say that it should not be encouraged. However, it is to say that we should not expect dramatic savings as the ultimate benefit.
“Greater use of Health IT is likely to further promote consolidation of the healthcare industry. Physicians in smaller practices will need to rely on larger entities to install and support their systems, even with the government subsidies. There will also be a need to link systems so that information can be shared across providers. The structure of the industry, therefore, is likely to change as this initiative moves forward.
On additional long-term implications:
“The other major long-term provision establishes a board to conduct comparative effectiveness analyses of new medical treatments. These will be used to determine which treatments will be eligible for reimbursement under Medicare, Medicaid, and SCHIP. Comparative effectiveness analyses compare new treatments to existing ones in terms of cost and effectiveness. They can result in decisions to deny coverage for new treatments if they do not offer measurable improvements in either respect. This is similar to mechanisms in place in a few other industrialized countries, most notably England, which has the National Institute for Clinical Excellence (NICE) to advise its national health system. However, in England, there is a government-run health care system that directly relies on NICE to set reimbursement policy. In the United States, the effect of the private sector will be indirect. Nevertheless, private insurers generally follow Medicare coverage decisions, and it is likely that they will do the same with comparative effectiveness decisions of the new board.
On the end result to healthcare reform:
“Neither of these long-term initiatives implements broad-scale healthcare reform. However, they may serve as “ice breakers” in that they initiate some elements of significant structural change. They make it easier to implement broader reform down the road, and they would likely each be part of a broader reform package.”
Robert Field, JD, MPH, PhD, is chair of the Department of Health Policy and Public Health at University of the Sciences in Philadelphia. His expertise extends into healthcare law and regulation, health system planning and development, and health policy analysis. Dr. Field recently published a book, "Health Care Regulation in America: Complexity, Confrontation and Compromise" which gives a comprehensive overview of the healthcare system in the United States. He is frequently asked to comment for major newspapers and broadcast outlets on late-breaking developments in healthcare.
Dr. Shannon Márquez Named Associate Dean for Academic Affairs of Mayes College
University of the Sciences in Philadelphia recently named Shannon Márquez, MEng, PhD, associate dean for academic affairs of Mayes College of Healthcare Business and Policy. Additionally, Dr. Márquez will join Mayes College as an associate professor in the Department of Health Policy and Public Health.
Dr. Márquez is a well-connected dynamic scholar and experienced administrator whose achievements have garnered local, national, and international recognition. She is a leader in the field of global health, with an expertise in examining global health, sustainable development, and the environmental burden of disease in developing Africa.
Previously, she served at the Temple University College of Health Professions as associate professor of public health and the director of the master of public health program in the Department of Public Health, and director of the Center for Global Health. Prior to joining Temple, Dr. Márquez was on the faculty at the University of Texas Health Science Center at Houston School of Public Health.
Dr. Márquez is currently one of eight members appointed by Philadelphia Mayor Michael Nutter to serve on the Philadelphia Board of Health. She has been a member of several professional organizations, scientific advisory, editorial, and peer-review panels, including the American Public Health Association, the American College of Preventive Medicine, the Association for Prevention Teaching and Research, the USEPA National Center for Environmental Research, the National Center on Minority Health and Health Disparities (NCMHD), the National Institute for Environmental Health Sciences (NIEHS), and the Journal for Tropical Medicine & Hygiene.
Dr. Márquez earned her PhD in environmental health sciences and engineering, with a focus in environmental management and policy, from the Gillings School of Global Public Health at the University of North Carolina-Chapel Hill, a master’s in environmental engineering from Texas A&M University, and a BS from Prairie View A&M University in Texas.
Written By: Sabrina Walter
Travel Grant Helps Grad Student Carrie Waterman to ASP Meeting in Athens
With an endless stream of traffic winding its way through a dense city populated with outcroppings of ancient ruins, Athens, Greece, was the backdrop for the 7th Joint Meeting of The American Society of Pharmacognosy (ASP) from August 3 – 8, 2008. The meeting brought together nearly 1,200 scientists and students from Europe, Asia, and the U.S.
(Captions: Carrie Waterman PhD PhCog'11 is recognized by Dr. Robert Krueger of Ferris State University with the Travel Grant from The American Society of Pharmacognosy. Dr. Ara DerMarderosian takes in the sights of Athens. "It's an old USP professor visiting old Grecian ruins," he quipped.)
Among the attendees was graduate student Carrie Waterman PhD PhCog'11. Waterman, who is advised by Dr. Ara DerMarderosian, presented her poster “Bioassay-guided isolation of African ethnobotanical anthelmintics.” She was there in large part due to a national travel award from the ASP which she obtained in conjunction with a grant writing class (see July 2008 Inside USP). The rest of her trip was made possible by an Abraham Glasser Fellowship and support from the College of Graduate Studies.
“It was a little bit culture and a little bit science,” Waterman said of her overall experience. Dr. DerMarderosian, also on hand in Greece, presented two posters by his other graduate students Vidhanchandra Jaiswal PhD PhCog'08 on pomegranate anthocyanins and Radhika Kota PhD PhCog'08, on bioactive principles in blueberry. University faculty, including Dr. John Porter, Dr. Guillermo Moyna, Dr. Diane Morel, Dr. James McKee and Professor Robert Smith, were coauthors on one or more of these posters and abstracts which were published in the international journal Planta Medica.
In addition to presentations, papers, and posters, Waterman and Dr. DerMarderosian enjoyed a taste of Greek life, including a performance by a Greek village dance group and visits to such local attractions as the Acropolis and Parthenon. The final day included a sea excursion to three Greek Islands.
USP Pharmaceutics Graduate Student Preeti Desai presented
at the NJPhAST Meeting in May
The 2008 New Jersey Pharmaceutical Association for Science and Technology (NJPhAST) GRADUATE SCHOLARSHIP award is given to recognize excellence in graduate research in the fields of pharmaceutical science and pharmaceutical technology. NJPhAST is a non-profit organization managed by a board of officers from the industry and the academia and has been providing a forum to pharmaceutical scientists for discussion, continuing education and the exchange of ideas on advances in Pharmaceutical Sciences and Technology for some 40 years. They have a membership of about 400 composed of scientists and engineers as well as suppliers of chemicals, equipment and services to the Pharmaceutical Industry. A one-time scholarship of $2000 is awarded to a graduate student for a research submission which, in judgment of NJPhAST is of the greatest scientific importance, the most original and of the highest quality. A graduate student at Long Island University, Sasank Chaitanya was the winner of the graduate scholarship for his outstanding research. However, 12 graduate students from the state of New Jersey, New York, and Pennsylvania were invited to participate as runner-up entries for the poster session at this event at Parsippany Hilton, NJ on May 22, 2008. Preeti Desai, a final year PhD candidate in the pharmaceutics program at University of the Sciences in Philadelphia was one of the invitees to participate in the poster session at this event. The event was followed by dinner, a podium presentation by Sasank Chaitanya (Topic: Kinetic and Thermodynamic Analysis of 10-Hydroxy-Camptothecin Hydrolysis at Physiological pH) and a presentation by Dr. Lawrence X. Yu, Director for Science at the Food and Drug Administration (Topic: Pharmaceutical Quality by Design: What Does It Mean to You) sponsored by Patterson-Kelley, Mendel Company and FMC Biopolymers.
.jpg)
The topic of Preeti’s poster presentation was ‘Study of Adsorption-Induced Structural Changes in Recombinant Human Growth Hormone using Fluorescence Spectroscopy’.
Research Summary: Therapeutic proteins tend to lose their stability and undergo aggregation/denaturation at the interface during formulation development. It is well documented that proteins undergo conformational changes upon adsorption at solid/liquid interfaces. Since unfolding of proteins can alter their biological activity and cause toxic and immunogenic problems in the body, there is a need to improve our knowledge about protein adsorption and resulting conformational changes. In order to provide a simplistic approach and to gain a better insight into the adsorption mechanism, a model system was chosen consisting of a well-characterized protein (recombinant human growth hormone, rhGH), a moderately hydrophobic and partly charged sorbent interface (polystyrene latex nanoparticles) and, an aqueous buffer system. Knowledge of the nature of interactions that control the behavior of proteins at solid/liquid interfaces is relevant in the search for new and better biomaterials for protein formulations. The current study was aimed at determining the changes in tertiary structure associated with the interaction of rhGH with negatively charged polystyrene nanoparticles by interpreting the observed fluorescence spectra of rhGH. The study has been carried out in conjunction with other spectroscopic technique such as circular dichroism and thermodynamic studies such as differential scanning calorimetry and isothermal titration calorimetry. Results from these studies will be applied for successful design of polymer-based nanoparticulate delivery system for controlled delivery of proteins in biodegradable microspheres.
Spotlight on USP Graduate Student Shilpa Viswanathan and her UN Internship Experience
Shilpa Viswanathan's UN internship Experience was highlighted in the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Connections Publication. She participated in the Knowledge Communication for Children in India (KCCI) internship program with UNICEF India this past June. It is a 10-week internship program organized every summer. Shilpa is a MS Pharmacy Administration student at USP and the ISPOR Student Chapter President.
Full Article from ISPOR STUDENT CORNER:
My UN Internship Experience ~ Prepared by Shilpa Viswanathan
SHILPA'S PUBLICATIONS:
- Viswanathan S. Risk factors for multidrug resistant tuberculosis in Africa: A Meta-analysis Med J Therapeut Africa. 2008; 1:73-9
- Viswanathan S. My UN Internship Experience. ISPOR Connections. 2007; 13(6): 26
- Viswanathan S. UNICEF and HIV/AIDS. Med J Therapeut Africa. 2007; 2:134
- McGhan WF, Tundia N, Quadri H, Viswanathan S, and Peterson AM. Evaluating an online
calculator for analyzing incremental net benefit and the expected value of perfect information
from patient level data. Value in Health. 2007; 10 (3): A 185 - Editor/Author. The Nest. 2004. (4th Edition).
The Nest is an annual publication of the Students Council, MET’s Institute of Pharmacy,
University of Mumbai, Mumbai, India
SHILPA'S PRESENTATIONS:
- Viswanathan S, McGhan WF. A cost-effectiveness analysis of TNF-α inhibitors in comparison to other strategies in the treatment of moderate-to-severe psoriasis: A decision analysis model. ISPOR 13th Annual International Meeting. Toronto, Canada
- Viswanathan S, Neville W, Patel E, Raparla S, McGhan WF. A cost-effectiveness model for smoking cessation using Varenicline. ISPOR 13th Annual International Meeting. Toronto, Canada
- McGhan WF, Tundia N, Quadri H, Viswanathan S, and Peterson AM. Evaluating an online calculator for analyzing incremental net benefit and the expected value of perfect information from patient level data. ISPOR 12th Annual International Meeting. Arlington, VA, USA, May 2007
SHILPA'S PROFESSIONAL AFFILIATIONS:
-
International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
President/Student member, USP-ISPOR student chapter (Sept 2007- May 2008)
Vice-president, USP-ISPOR student chapter (Oct 2006- Sept 2007) -
Medical Journal Therapeutics Africa (MJOTA)
Member of Editorial Board (Dec 2007- present)
Vijaya Swaminathan Successfully Defends her Thesis and Earns her PhD in Pharmaceuitcs
About Vijaya: Vijaya Swaminathan was born in Mumbai, India. She graduated with a degree in Pharmacy (B. Pharm) from the Bombay College of Pharmacy, University of Mumbai, India in 2002. On completion of her undergraduate degree she pursued her interest in the field of Pharmaceutics by enrolling in the Ph.D. program at the University of the Sciences in Philadelphia in August 2002. During her time at USP, Vijaya has presented at 5 posters at national and regional meetings and 1 at an international meeting. She is the lead author in a publication in the Journal of Biomaterials Science, Polymer edition. She won the best poster award at the Philadelphia Pharmaceutical Forum’s poster night event in 2007. She also served as a teaching assistant in the Departments of Chemistry and Pharmaceutics. She thoroughly enjoyed her experience here at USP, and believes that the faculty and graduate students played an important role in the learning process and also making her experience in Philadelphia worth it.
Research Summary :
Biodegradable polymers have been widely investigated in a broad range of applications from micro capsules for controlled drug delivery to scaffolds in tissue engineering. The ability to alter polymer properties for an intended application makes these polymers indispensable. Poly-L-lactic acid (PLLA) due to its high tensile strength, long degradation time was our polymer of choice for reservoir delivery applications. Polyehtylene glycol (PEG) was included as a blend to improve the flexibility of PLLA. This aim of the research was to thoroughly characterize PLLA:PEG membranes and test their potential for dermal regeneration applications. The results showed that the membranes possessed high barrier efficacy, high mechanical strength that was comparable to standard membranes and these properties were retained up to 6 weeks in vitro. The membranes also supported the attachment and proliferation of human dermal fibroblasts (HDFa), thus indicating the feasibility of PLLA:PEG membranes as potential candidates for skin regeneration applications.
Two USP graduate students in the Chemistry programs recently won awards
Carrie Waterman, 3rd year graduate student in Pharmacognosy
Carrie won on a travel award from the American Society for Pharmacognosy in support of attending their next meeting in Athens, Greece ($1000). According to the ASP, only three such awards have been given this year.
Whelton Miller, 2nd year graduate student in Chemistry
Whelton
won the William Penn award for his poster presentation at the local ACS meeting (8th Annual Graduate Poster Session) in January 2008. This award was also highly competitive - there were over 60 presenters from a number of institutions, including Temple University, University of Delaware, Drexel University and University of Pennsylvania.
Congratulations Carrie Waterman & Whelton Miller!
Pharmaceutical Business Online MBA Spring 2008 Starting January 14th
USP’s Executive MBA Online curriculum features teaching methods that offer you anywhere/anytime learning and virtual group collaboration.
To view the 22-month online program comprised of a 36-credit curriculum click here
Studying Health Care In Japan
As a joint effort of the department of pharmaceutical and healthcare business and the department of health policy and public health, 12 graduate students visited Japan from July 1–11.
The business students participated as part of the international pharmaceutical business course and the health policy students as part of a special topics elective. Bruce Rosenthal (pharmaceutical and healthcare business) and Dr. Robert Field (health policy and public health) accompanied the group. They meet with Japanese professionals from the pharmaceutical and health care fields. Some of the company visits on the agenda included Eizai Headquarters, Dai-Ichi R&D Center, A-Z Japan and Wyeth Japan. The students also meet with students from several top-level universities including Tokyo University as well as attended meetings with prominent academic researchers and government officials.
To see more photographs from the trip Click Here
Contact: Brian Kirschner (215-895-1186)
Health Care Regulation in America: Complexity, Confrontation and Compromise
Breakthrough publication by The College of Graduate Studies Health Policy Director
Robert I. Field, JD, MPH, PhD, Oxford University Press, 2007
Regulation shapes all aspects of America's fragmented health care industry, from the flow of dollars to the communication between physicians and patients. It is the engine that translates public policy into action. While the health and lives of patients, as well as almost one-sixth of the national economy depend on its effectiveness, health care regulation in America is bewilderingly complex. Government agencies at the federal, state, and local levels direct portions of the industry, but hundreds of private organizations do so as well. Some of these overseers compete with one another, some conflict, and others collaborate. Their interaction is as important to the provision of health care as are the laws and rules they implement.
Health Care Regulation in America is a guide to this regulatory maze. It succinctly recaps the past and present conflicts that have guided the oversight of each industry segment over the past hundred years and explains the structure of regulation today. To make the system comprehensible, this book also presents the sweep of regulatory policy in the context of the interests, values, goals, and issues that guide it. Chapters cover the process of regulation and each key area of regulatory focus - professionals, institutions, financing arrangements, drugs and devices, public health, business relationships, and research.
Learn more about Health Care Regulation in America on the publisher's website.
